ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1380	National Cancer Institute	Html	en	Colorectal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing colorectal cancer and about research aimed at the prevention of this disease.	colon cancer death 0.503164 colorectal adenoma chemoprevention 0.469587 mg/day ASA group 0.474963 Engl J Med 0.695761 colorectal cancer risk 0.569497 American Cancer Society 0.478754 cancer prevention study 0.51311 Br J Cancer 0.490702 case-control study 0.528084 CRC mortality rates 0.469166 Ann Intern Med 0.669327 Int J Cancer 0.468816 colorectal cancer 0.947004 fatal colorectal cancer 0.499741 advanced colorectal adenomas 0.4802 colon cancer prevention 0.492834 CRC incidence 0.472239 Natl Cancer Inst 0.758173 human colon cancer 0.480578 hereditary nonpolyposis colorectal 0.489202 distal colon cancer 0.492725 colorectal adenomatous polyps 0.518043 colorectal adenoma prevention 0.476577 long-term cancer incidence 0.468066 familial adenomatous polyposis 0.503867	et al. 0.597227 familial colorectal cancer 0.51297 large bowel cancer 0.489321 colorectal adenomas 0.590599 previous colorectal cancer 0.507755 nonpolyposis colorectal cancer 0.531539 cohort study 0.504026 Cancer Epidemiol Biomarkers 0.584507 hereditary colon cancer 0.485595 fatal colon cancer 0.501384 PUBMED Abstract 0.577579 CRC mortality 0.486759 Health Study 0.488018 National Cancer Institute 0.488273 Epidemiol Biomarkers Prev 0.558059 colorectal cancer incidence 0.562507 colorectal cancer disparities 0.516267 common colorectal cancer 0.511542 colorectal cancer rates 0.517039 colon cancer 0.785918 Abstract 0.678628 colon cancer risk 0.507338 in-trial cancer deaths 0.471053 colorectal cancer mortality 0.563581	CLICK HERE
1447	National Cancer Institute	Html	null	Unusual Cancers of Childhood Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others.			CLICK HERE
1611	National Cancer Institute	Html	en	Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version	Serious, disabling, and life-threatening chronic health conditions adversely affect the health of aging childhood cancer survivors. Learn about the cardiovascular, cognitive, psychosocial, digestive, endocrine, immune, musculoskeletal, reproductive, and urinary late effects and subsequent neoplasms that contribute to a high burden of morbidity in childhood cancer survivors.	adult cancer survivors 0.344142 childhood leukemia survivors 0.307057 Childhood Cancer Guideline 0.302298 childhood cancer therapy 0.296791 long-term cancer survivors 0.295333 childhood cancer survivors 0.499567 Engl J Med 0.269755 Br J Cancer 0.261959 Cancer Survivor cohort 0.269169 Int J Cancer 0.266011 Ann Intern Med 0.263377 5-year survivors 0.295172 cancer survivors research 0.286942 Radiat Oncol Biol 0.277048 breast cancer surveillance 0.269328 adult survivors 0.315122 Hudson MM 0.309712 young adult cancer 0.340977 British Childhood Cancer 0.326521 Natl Cancer Inst 0.402086 survivor study cohort 0.273371 Clin Cancer Res 0.263669 Irradiated Childhood Cancer 0.298512 childhood cancer 0.912384 cancer survivor study 0.693286	et al. 0.431618 late effects 0.3275 long-term survivors 0.333244 cohort study 0.263432 Cancer Epidemiol Biomarkers 0.265429 pediatric cancer survivors 0.286679 PUBMED Abstract 0.35078 Pediatr Blood Cancer 0.447984 radiation-induced breast cancer 0.26406 breast cancer risk 0.280733 Abstract 0.467444 Clin Oncol 0.515912 breast cancer 0.391476 Oncol Biol Phys 0.278259 childhood cancer survivor 0.771953 Cancer Guideline Harmonization 0.260525 young cancer survivors 0.275759 childhood cancer registry 0.291062 long-term follow-up guidelines 0.273165 Cancer J Clin 0.270171 report 0.265432 childhood cancer treatment 0.287484 oncology group 0.32484 long-term childhood cancer 0.311378	CLICK HERE
2052	National Cancer Institute	Html	es	Terapias biológicas para el cáncer	Hoja informativa sobre la función del sistema inmunitario; describe la acción de las terapias biológicas.	Haluska FG 0.420038 Redig AJ 0.419038 ARN mensajero 0.423865 killer cell-based immunotherapy 0.432963 células hijas 0.643617 Canese P 0.41842 O'Day SJ 0.419485 clinical applications 0.420154 we tilt 0.419245 immune system 0.418755 altas dosis 0.418691 linfocitos b 0.794775 antígeno cd52 0.453352 Translational Medicine 0.419593 Comité Asesor 0.418458 biological therapy 0.455134 Internal Medicine 0.419677 Estados Unidos 0.448833 Expert Opinion 0.421046 linfocitos t 0.82421 intrusos foráneos 0.428976 towards immune-mediated 0.419994 PubMed Abstract 0.779921 metastatic melanoma 0.424461 madre sanas formadoras 0.440701	terapia modificadora 0.491313 Abeloff's Clinical Oncology 0.43296 mARN blanco 0.422446 antígeno cd20 0.515911 bacteria bacilo 0.445994 Improved survival with 0.436486 invasores foráneos 0.480692 células madre 0.955075 molécula her-2 0.428705 Cancer immunology 0.420503 Ningún virus 0.447968 on tumor immunology 0.437409 McDermott DF 0.418981 envoltorio protector 0.421713 IFN)-dependent activation 0.420375 terapia biológica usa 0.634008 90Y‑ibritumomab tiuxetán 0.424391 ingeniería genética 0.421138 sistema inmunitario.  aún 0.450887 escasa toxicidad 0.422699 biológica usa organismos 0.547748 Aún más 0.468819 virus vector 0.444624 New England Journal 0.430623	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
2972	National Cancer Institute	Video	en	Reach out and offer her a helping hand: A Smokefree Pregnancy Video	We know quitting smoking is tough, and becoming pregnant doesn't suddenly make it easier. "Reach Out & Offer Her a Helping Hand" is intended to rally the American public's support for all mamas-to-be trying to put out the cigs. For more info on how you can help that special lady in your life quit smoking for good, visit: women.smokefree.gov	SmokefreeWomen 0.826013 Healthier Summer Sweets 0.545266 04 0.327172 women.smokefree.gov 0.329 NCI Smokefree 0.680659 Good Night 0.430291 Positive Environment 0.433577 life 0.329079 NCI Smokefree Pregnancy 0.635056 Challenge 0.408491 Motivator 0.335402 American public 0.460348 smoking 0.356739 smoke smell 0.447387 Smokefree Voices Video 0.623419 Contest 0.32649 How-to Video 0.421251 Blog 0.32681 views 0.825633 busy schedule 0.430343	info 0.329188 Helping Hand 0.601743 Reach 0.325318 Smokefree Women 0.817171 Voiceover 0.330521 Duration 0.991806 autoplay 0.374808 NCI Smokefree Women 0.669737 De-stress 0.333641 special lady 0.458682 Offer 0.359013 Street Team Video 0.555716 Clean house 0.432823 newest video 0.459372 Fitting fitness 0.42414 visit 0.325778 cigs 0.329305 support 0.329395 Healthy Body Image 0.533317	CLICK HERE
3551	National Cancer Institute	Html	en	Cancer Statistics	Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses.	cancer statistics 0.699332 major impact 0.569457 new screening test 0.610486 United States 0.848591 Asian/Pacific Islander women 0.623563 cancer death rate 0.734611 cancer deaths 0.662668 thyroid cancer 0.618391 SEER program website 0.613262 renal pelvis cancer 0.675159 population-based cancer registries 0.661094 African American men 0.620993 number 0.579668 new cancer cases 0.74726 American Cancer Society 0.655347 pancreatic cancer 0.619919 bladder cancer 0.619451 cancer-related deaths 0.575865 average age 0.568157 individual cancer types 0.652597 North American Association 0.605716 racial/ethnic group 0.570832 cancer care 0.615369 cancer diagnosis 0.664799	breast cancer 0.617639 rectum cancer 0.622513 large groups 0.569141 risk factor 0.614571 U.S. population 0.610565 people 0.571698 statistical trends 0.613522 age-adjusted mortality 0.572947 prostate cancer 0.619132 bronchus cancer 0.62075 Central Cancer Registries 0.654709 cancer survivors 0.603772 cancer mortality 0.652323 policy makers 0.566593 Understanding Cancer Prognosis 0.676403 endometrial cancer 0.620993 cancer 0.951216 new cases 0.679157 cancer incidence 0.694185 cancer death rates 0.665983 SEER Cancer Statistics 0.665479 overall cancer death 0.735155 cancer rates 0.609223	CLICK HERE
14601	National Cancer Institute	Html	en	Childhood Vascular Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood vascular tumors.	lesions 0.459907 body 0.444762 PDQ cancer information 0.428885 steroid therapy 0.431929 malignant tumors 0.409372 clinical trials 0.622735 aggressive vascular tumors 0.43708 congenital hemangioma 0.425723 cancer information summary 0.40263 Diagnostic Tests 0.677407 liver 0.469914 lobular capillary hemangioma 0.410892 blood vessels 0.494734 pyogenic granuloma 0.401485 diffuse tumors 0.399482 benign vascular tumor 0.531292 vascular tumors 0.851122 clinical trial 0.485314 spindle cell hemangiomas 0.4591 malignant vascular tumors 0.461238 radiation therapy 0.585507 following 0.416254 late effects 0.40785 General Information section 0.953371	treatment 0.883924 blood vessel 0.40513 childhood vascular tumor 0.423751 skin 0.519128 vascular tumor 0.671886 benign vascular tumors 0.586046 infantile hemangiomas 0.495631 signs 0.415044 treatment clinical trials 0.412572 procedures 0.39986 multiple lesions 0.412762 tumor cells 0.435841 new treatment 0.424941 topical beta-blocker therapy 0.421578 kaposiform hemangioendothelioma 0.442163 hemangiomas 0.524006 risk factor 0.415027 childhood vascular tumors 0.50237 benign tumors 0.412061 blood vessel tumors 0.39943 kaposi sarcoma 0.437901 standard treatment 0.431582 diffuse liver tumors 0.410968 surgery 0.449251	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE